$AZN Market Cap:
Research Board Inbox Deep Research Not Interested Shortlisted

$AZN SEC Filings

Filing Filed On
BRILINTA MET PRIMARY ENDPOINT IN PHASE III THALES TRIAL IN STROKE 27 Jan 2020
ASTRAZENECA TO RECOVER THE GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN 27 Jan 2020
ASTRAZENECA DIVESTS RIGHTS TO ESTABLISHED HYPERTENSION MEDICINES 27 Jan 2020
PHASE II DESTINY-GASTRIC01 TRIAL OF ENHERTU VERSUS CHEMOTHERAPY MET PRIMARY ENDP 27 Jan 2020
IMFINZI AND TREMELIMUMAB GRANTED ORPHAN DRUG DESIGNATION IN THE US FOR LIVER CAN 21 Jan 2020
LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR HRR-MUTATED 21 Jan 2020
UPDATE ON PHASE III STRENGTH TRIAL FOR EPANOVA IN MIXED DYSLIPIDAEMIA 13 Jan 2020
LYNPARZA REGULATORY SUBMISSION GRANTED PRIORITY REVIEW IN THE US FOR 1ST-LINE MA 13 Jan 2020
LOKELMA APPROVED IN CHINA FOR THE TREATMENT OF ADULT PATIENTS WITH HYPERKALAEMIA 06 Jan 2020
FARXIGA GRANTED FDA PRIORITY REVIEW FOR PATIENTS WITH HEART FAILURE WITH REDUCED 06 Jan 2020
TOTAL VOTING RIGHTS 02 Jan 2020
LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA- 30 Dec 2019
ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP 23 Dec 2019
ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB 23 Dec 2019
ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO 20 Dec 2019
FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCER 17 Dec 2019
SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIA 16 Dec 2019
IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALL 12 Dec 2019
TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASE 11 Dec 2019
LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADV 05 Dec 2019